Leads to first all-LED medical device that regenerates hair.
No chemicals. No pills. Just light.
DURHAM, N.C.–(BUSINESS WIRE)–REVIAN Inc. (formerly PhotonMD Inc.), a medical technology company dedicated to stimulating the body’s natural processes to rejuvenate hair and skin with light, is pleased to announce that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,265,258 – the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body.
“This is a groundbreaking approach to the therapeutic use of light,” said Dr. Nathan Stasko, co-inventor and Executive Chairman REVIAN Inc. “We set out to decode the spectrum of light and identify which wavelengths encourage cells, tissues and organs to repair themselves.”
The claims in this issued patent cover the use of specific wavelengths of LED light to stimulate the body’s cellular generation of nitric oxide as well as to release the body’s natural nitric oxide reserves. Nitric oxide has a remarkably diverse range of biological functions as it is involved in the proper function of virtually every organ in the human body, and its decline is linked to many degenerative diseases of aging.
“By stimulating the body’s internal mechanisms for the generation and release of nitric oxide, we are able to realize the therapeutic benefits of nitric oxide in the body without the challenges of pharmaceutical drug development,” continued Dr. Stasko.
The assembly of such an experienced team in both LED and medical discovery to address the needs of the body is unprecedented. The group of inventors listed on the patent represents the same fusion of life science and light science that their invention embodies. Among them, this group has over 500 patent filings and over 250 issued patents, the bulk of which can be attributed to Gerry Negley, co-inventor and arguably the foremost expert on the creation and delivery of LED light. He is inventor or co-inventor on about every major advancement in LED-based light. Now REVIAN, and its parent company KNOW Bio, are unleashing the power of LED technology to create optimum biological outcomes.
“The body’s natural capabilities to heal and regenerate itself can be unlocked using light,” said Gerry Negley. “With this technology, we are doing just that by using a proprietary combination of monochromatic LEDs.”
Medical LED systems are possible because of the decades of innovation in semiconductor materials that have now created the ability for light to be delivered in precise, narrow bands that lead to direct engagement of biological tissues. With power levels at or exceeding the output of lasers, higher efficiency LEDs enable devices that are durable, smaller, lightweight and far more comfortable and convenient for people to use.
REVIAN RED is the first product to employ the therapeutic advances enabled by combining LED technology and nitric oxide medical research. This advanced medical device is clinically proven to stop hair loss and grow new hair, providing a potentially life-changing treatment for men and women suffering from androgenetic alopecia.
“Our patented dual-band technology can give new hope to the estimated 50 million men and 30 million women suffering from androgenetic hair loss in the United States and to hundreds of millions more around the globe,” said Brian Johnson, President REVIAN Inc. “When you add a second wavelength and use LEDs to provide a whole new patient experience designed from the ground up to be comfortable, effective, safe and convenient—you have REVIAN RED, the most technologically advanced answer for these millions of sufferers.”
About REVIAN RED
The REVIAN RED System is an FDA cleared, wireless wearable cap controlled by a mobile “smart” app that functions to provide a hair loss treatment for men and women using LED light. The patented dual-band, LED technology provides broader scalp coverage and better skin penetration than red lasers used in low level laser therapy (LLLT). Dual wavelengths of LED light facilitate and accelerate scalp healing, allowing the body to renew cells associated with hair growth and retention.
Indications for use: The REVIAN RED System is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton classifications of IIa–V patterns of hair loss and to treat androgenetic alopecia and promote hair growth in females who have Ludwig-Savin Scale I-1 to I-4, II-1, II-2 or frontal patterns of hair loss; both with Fitzpatrick Skin Types I–IV.
About the Patent
Title: |
Systems and Methods for Phototherapeutic Modulation of Nitric Oxide |
||
Patent No. |
10,265,258 |
||
Inventors: |
Nathan Stasko, Nicholas W. Medendorp Jr., Gerald H. Negley, and Katelyn P. Reighard |
About REVIAN
REVIAN is a medical technology innovator dedicated to stimulating the body’s natural processes to rejuvenate hair and skin with light. We create products that precisely deliver light and allow people to experience its regenerative potential in the convenience of their own home. We are committed to partnering with health-care providers and other caring professionals to deliver meaningful results, backed by scientific data. For more information, visit www.revian.com.
REVIAN Inc. is headquartered in Durham, is an operating subsidiary of KNOW Bio, LLC. and was formerly known as PhotonMD Inc.
Contacts
Media Contacts
Genevieve Britton
Pascale Communications, LLC
genevieve@pascalecommunications.com
(512) 774-0735
Audra Friis
Pascale Communications, LLC
audra@pascalecommunications.com
(917) 519-9577
Investor Contact:
John Oakley, Chief Financial Officer
KNOW BIO, LLC
joakley@knowbiollc.com
(919) 939-7715
Novel technology recognized for its groundbreaking design and patient-centric innovationSAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative…
One Small Step Pairs Strangers With Opposing Political Beliefs for One-on-One Conversations, Not to Debate…
Positioning Navigate as a Leader in Comprehensive Wellbeing Solutions WEST DES MOINES, Iowa, July 8,…
SILVER SPRING, Md., July 8, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration…
SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring…
CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced that Enabling Technologies Consortium…